Temozolomide: Clinical Trials

944 trials of Temozolomide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

430 completed, 123 recruiting, 119 terminated, 115 unknown. 605 Phase 2, 347 Phase 1, 101 Phase 3, 21 Early Phase 1, 19 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 2605Completed 265, Recruiting 82, Unknown 82, Terminated 71, Active not recruiting 56, Not yet recruiting 32, Withdrawn 14, Suspended 2, Enrolling by invitation 1
Phase 1347Completed 167, Terminated 55, Recruiting 49, Active not recruiting 29, Unknown 25, Not yet recruiting 13, Withdrawn 7, Suspended 2
Phase 3101Completed 32, Recruiting 17, Unknown 17, Active not recruiting 13, Terminated 11, Not yet recruiting 8, Withdrawn 3
Early Phase 121Completed 8, Recruiting 5, Active not recruiting 3, Withdrawn 3, Terminated 1, Unknown 1
Not applicable19Completed 6, Unknown 6, Terminated 3, Recruiting 2, Not yet recruiting 1, Withdrawn 1
Phase 44Completed 3, Not yet recruiting 1

Follow Temozolomide: new trials by email Literature Review of Temozolomide trials Research Report on Temozolomide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma
Temozolomide (TMZ) - Cutaneous Melanoma
Phase 2Not yet recruitingAssistance Publique Hopitaux De Marseille282027-06-012026-09-08
Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma
Phase 1 / Phase 2Not yet recruitingUniversity of Nebraska412027-06-012026-10-05
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV)
Phase 1 / Phase 2Not yet recruitingSabine Mueller, MD, PhD972027-06-012026-11-09
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype
Phase 2 / Phase 3Not yet recruitingEverfront Biotech Co., Ltd.1752027-04-012026-09-10
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4
Phase 2Not yet recruitingGerman Cancer Research Center2162027-02-012026-10-22
NG101m Adjuvant Therapy in Glioblastoma Patients
Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme
Phase 1 / Phase 2Not yet recruitingNeuGATE Theranostics522027-01-012025-10-21
Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform
Temozolomide, Disulfiram, Copper - Glioblastoma Multiforme
Phase 2Not yet recruitingOlympion Medical Center322027-01-012025-05-25
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant - Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm
Phase 2Not yet recruitingRoswell Park Cancer Institute602026-12-152026-10-20
PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Contrast-enhanced Magnetic Resonance Imaging, Magnetic Resonance Imaging - Glioblastoma
Phase 3Not yet recruitingJonsson Comprehensive Cancer Center602026-12-012026-07-07
Novel endOvascular Therapy With beVAcizumab and Cannabinoids for Glioblastoma
Bevacizumab - GBM
Phase 1Not yet recruitingUnity Health Toronto62026-12-012026-11-02
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma
Phase 1 / Phase 2SuspendedWashington University School of Medicine682026-11-302026-10-30
Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma
Naxitamab and GM-CSF in combination with irinotecan and temozolomide, Dinutuximab. Immunotherapy, DFMO - Neuroblastoma
Phase 2RecruitingGiselle Sholler1012026-11-262026-11-12
Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial
Biospecimen Collection, Computed Tomography, F-18 Fluoroethyltyrosine - Glioblastoma, IDH-Wildtype
Phase 3Not yet recruitingMayo Clinic2922026-11-102026-11-13
Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
Tris-CAR-T cell injection, Ommaya reservoir implantation, Temozolomide (TMZ) - Newly Diagnosed Glioblastoma, IDH-wildtype
Phase 2 / Phase 3Not yet recruitingBeijing Tiantan Hospital602026-10-152026-10-14
TRINITY TRIAL; Trial Of PRRT Plus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETS
Capecitabine, Temozolomide (TMZ), Lutetium Lu 177 Dotatate - Gastroenteropancreatic Neuroendocrine Tumors
Phase 3Not yet recruitingTata Memorial Hospital1232026-10-112026-11-02
Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer
NLG802 (indoximod Prodrug), Temozolomide - Progressive Pediatric Brain Cancer
Phase 1Not yet recruitingLumos Pharma302026-10-082026-07-28
A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated
Teniposide Combined with Temozolomide - Newly Diagnosed Glioblastoma, MGMT-Unmethylated Glioblastoma
Not applicableNot yet recruitingSun Yat-sen University722026-10-012026-10-26
Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma
Adebrelimab, Temozolomide, Procedure:Hyperbaric Oxygen Therapy - Glioblastoma
Phase 2Not yet recruitingWei Jiang942026-10-012026-08-27
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms
Phase 1 / Phase 2Not yet recruitingAdvenchen Pharmaceuticals, LLC.1382026-09-012026-09-10
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Glioblastoma (GBM)
Phase 1 / Phase 2Not yet recruitingBreakBio Corp102026-09-012026-08-19

Showing 20 of 944. Sign in to see all of them.

Conditions studied

Glioblastoma (416)  ·  Brain Neoplasms (165)  ·  Glioma (164)  ·  Gliosarcoma (132)  ·  Astrocytoma (116)  ·  Central Nervous System Neoplasms (110)  ·  Melanoma (76)  ·  Oligodendroglioma (74)  ·  Neuroblastoma (45)  ·  Medulloblastoma (33)  ·  Neoplasms (33)  ·  Recurrence (32)  ·  Neoplasm Metastasis (29)  ·  Ependymoma (26)  ·  Sarcoma (24)

Sponsors

National Cancer Institute (NCI) (60)  ·  M.D. Anderson Cancer Center (30)  ·  Memorial Sloan Kettering Cancer Center (25)  ·  Duke University (24)  ·  Merck Sharp & Dohme LLC (22)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (19)  ·  European Organisation for Research and Treatment of Cancer - EORTC (17)  ·  Mayo Clinic (13)  ·  Children's Oncology Group (12)  ·  University of California, San Francisco (12)  ·  Northwestern University (11)  ·  Jonsson Comprehensive Cancer Center (10)  ·  Sun Yat-sen University (10)  ·  Alliance for Clinical Trials in Oncology (9)  ·  Dana-Farber Cancer Institute (9)

Countries

United States (590)  ·  China (100)  ·  France (89)  ·  Canada (77)  ·  Germany (70)  ·  Italy (70)  ·  United Kingdom (66)  ·  Spain (59)  ·  Australia (54)  ·  Netherlands (48)  ·  Switzerland (47)  ·  Belgium (35)  ·  Austria (32)  ·  Denmark (24)  ·  Israel (23)

Top investigators

David A. Reardon, MD (8)  ·  Henry S. Friedman, MD (8)  ·  Annick Desjardins, MD, FRCPC (5)  ·  Jeffrey Raizer, MD (4)  ·  Maryam Fouladi, MD (4)  ·  Roger Stupp, MD (4)  ·  Svetomir Markovic, MD, PhD (4)  ·  Annick Desjardins, MD (3)

Results publications

PMID 36346112, PMID 29982805, PMID 32691060, PMID 16200343, PMID 17705175, PMID 23243055, PMID 24309981, PMID 24344045, PMID 24552317, PMID 25113840, PMID 28039367, PMID 29077941, PMID 29412784, PMID 33842889, PMID 36188432, PMID 38197800, PMID 39571596, PMID 11772431, PMID 12039921, PMID 12649108, PMID 12675312, PMID 12763216, PMID 12829671, PMID 12947072, PMID 13680158, PMID 14769138, PMID 15073861, PMID 15173079, PMID 15234047, PMID 15251162, PMID 15565574, PMID 15758009, PMID 15758010, PMID 16192602, PMID 16203762, PMID 16234526, PMID 16260693, PMID 16321761, PMID 16520474, PMID 16530701, PMID 16735709, PMID 16786120, PMID 16899365, PMID 16982773, PMID 17031561, PMID 17114659, PMID 17134114, PMID 17252015, PMID 17609661, PMID 17664336

NIH funding

2023 (10), 2018 (8), U10CA180868 (8), U10CA180886 (8), 2008 (6), 2009 (6), P30CA008748 (6), P30CA060553 (6), U10CA180821 (6), 2017 (5), 2019 (5), 2025 (5), P30CA043703 (5), U01CA062475 (5), U10CA021661 (5)